Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: neural regeneration peptides - CuroNZ

Drug Profile

Research programme: neural regeneration peptides - CuroNZ

Alternative Names: Neuro-regenerative peptides; Neuronal regeneration peptides; NNZ-4921; NRPs programme

Latest Information Update: 27 Nov 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Metabolic Pharmaceuticals; Neuren Pharmaceuticals
  • Developer CuroNZ
  • Class Nerve growth factors; Neuropeptides
  • Mechanism of Action Cell differentiation stimulants; CXCR4 receptor modulators; Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Amyotrophic lateral sclerosis; Multiple sclerosis; Peripheral nervous system diseases; Retinal disorders; Stroke
  • Discontinued Spinal cord injuries

Most Recent Events

  • 27 Nov 2017 Preclinical development for Amyotrophic lateral sclerosis, Multiple sclerosis, Peripheral nervous system diseases, Retinal disorders and Stroke is ongoing in New Zeland (CuroNZ website, November 2017)
  • 27 Nov 2017 Discontinued - Preclinical for Spinal cord injuries in New Zealand (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in New Zealand (Parenteral, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top